Logic would say cancer drugs can’t work if something is keeping them out of the tumor. The latest startup from the Bob Langer/Polaris Partners factory floor just got $22 million to clear out some of the barriers around tumors, and make it easier for some of the exciting new immuno-oncology drugs to do what they do best.
Cambridge, Mass.-based Xtuit Pharmaceuticals, founded in 2011 by Polaris, is announcing today it has pulled in $22 million in Series A financing. NEA led the round, and was joined by Polaris, and new investors CTI Life Sciences, Arcus Ventures and Omega Funds. The scientific founders are Rakesh Jain of Massachusetts General Hospital, Robert Langer of MIT, and Ron Evans of the Salk Institute. Alan Crane of Polaris is the founding CEO.